Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis.

Smolders J, Peelen E, Thewissen M, Cohen Tervaert JW, Menheere P, Hupperts R, Damoiseaux J.

PLoS One. 2010 Dec 13;5(12):e15235. doi: 10.1371/journal.pone.0015235.

2.

Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects.

Correale J, Ysrraelit MC, Gaitán MI.

J Immunol. 2010 Oct 15;185(8):4948-58. doi: 10.4049/jimmunol.1000588. Epub 2010 Sep 20.

3.

Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis.

Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, Dwyer T, Gies P, van der Mei I.

Ann Neurol. 2010 Aug;68(2):193-203. doi: 10.1002/ana.22043.

PMID:
20695012
4.

T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH.

Clin Exp Immunol. 2010 Oct;162(1):1-11. doi: 10.1111/j.1365-2249.2010.04143.x. Review.

5.

The role of antigen presenting cells in multiple sclerosis.

Chastain EM, Duncan DS, Rodgers JM, Miller SD.

Biochim Biophys Acta. 2011 Feb;1812(2):265-74. doi: 10.1016/j.bbadis.2010.07.008. Epub 2010 Jul 15. Review.

6.

Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.

Mowry EM, Krupp LB, Milazzo M, Chabas D, Strober JB, Belman AL, McDonald JC, Oksenberg JR, Bacchetti P, Waubant E.

Ann Neurol. 2010 May;67(5):618-24. doi: 10.1002/ana.21972.

PMID:
20437559
7.

A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis.

Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D'Souza C, Ursell M, O'Connor P.

Neurology. 2010 Jun 8;74(23):1852-9. doi: 10.1212/WNL.0b013e3181e1cec2. Epub 2010 Apr 28. Erratum in: Neurology. 2010 Aug 3;75(5):480. Neurology. 2010 Sep 14;75(11):1029. Dosage error in article text.

8.

Does vitamin D modulate asymmetric dimethylarginine and C-reactive protein concentrations?

Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD.

Am J Med. 2010 Apr;123(4):335-41. doi: 10.1016/j.amjmed.2009.09.024.

PMID:
20362753
9.

Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers.

Vogt MH, ten Kate J, Drent RJ, Polman CH, Hupperts R.

Mult Scler. 2010 Apr;16(4):443-9. doi: 10.1177/1352458509359723. Epub 2010 Jan 19.

PMID:
20086024
10.

Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1.

Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO.

Eur J Immunol. 2009 Nov;39(11):3147-59. doi: 10.1002/eji.200839103.

11.

Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes.

Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM; Type 1 Diabetes TrialNet Research Group.

Diabetes. 2009 Nov;58(11):2588-95. doi: 10.2337/db09-0249. Epub 2009 Aug 12.

12.

Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases.

Fernandes de Abreu DA, Eyles D, Féron F.

Psychoneuroendocrinology. 2009 Dec;34 Suppl 1:S265-77. doi: 10.1016/j.psyneuen.2009.05.023. Review.

PMID:
19545951
13.

Autoimmune T cell responses in the central nervous system.

Goverman J.

Nat Rev Immunol. 2009 Jun;9(6):393-407. doi: 10.1038/nri2550. Review.

14.

Immunomodulatory effects of Vitamin D in multiple sclerosis.

Correale J, Ysrraelit MC, Gaitán MI.

Brain. 2009 May;132(Pt 5):1146-60. doi: 10.1093/brain/awp033. Epub 2009 Mar 24.

PMID:
19321461
15.

Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective.

Kuchuk NO, van Schoor NM, Pluijm SM, Chines A, Lips P.

J Bone Miner Res. 2009 Apr;24(4):693-701. doi: 10.1359/jbmr.081209.

16.

Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis.

Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R.

Mult Scler. 2008 Nov;14(9):1220-4. doi: 10.1177/1352458508094399. Epub 2008 Jul 24.

PMID:
18653736
17.

Elevated serum inflammatory markers in post-poliomyelitis syndrome.

Fordyce CB, Gagne D, Jalili F, Alatab S, Arnold DL, Da Costa D, Sawoszczuk S, Bodner C, Shapiro S, Collet JP, Robinson A, Le Cruguel JP, Lapierre Y, Bar-Or A, Trojan DA.

J Neurol Sci. 2008 Aug 15;271(1-2):80-6. doi: 10.1016/j.jns.2008.03.015. Epub 2008 May 12.

PMID:
18474371
18.

Vitamin D as an immune modulator in multiple sclerosis, a review.

Smolders J, Damoiseaux J, Menheere P, Hupperts R.

J Neuroimmunol. 2008 Feb;194(1-2):7-17. doi: 10.1016/j.jneuroim.2007.11.014. Epub 2008 Jan 4. Review.

PMID:
18177949
19.

Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes.

Banwell B, Bar-Or A, Cheung R, Kennedy J, Krupp LB, Becker DJ, Dosch HM; Wadsworth Pediatric Multiple Sclerosis Study Group.

Ann Neurol. 2008 Jan;63(1):98-111.

PMID:
17932975
20.

Safety of vitamin D3 in adults with multiple sclerosis.

Kimball SM, Ursell MR, O'Connor P, Vieth R.

Am J Clin Nutr. 2007 Sep;86(3):645-51.

PMID:
17823429

Supplemental Content

Support Center